Teniposide after prior therapy for c-Myc–driven extensive-stage small cell lung cancer
Official title: Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer
Run by Shanghai Pulmonary Hospital, Shanghai, China · NCT06758700 · Data updated 2026-11-12
This will try teniposide in people with extensive-stage small cell lung cancer driven by high c-Myc who have progressed after standard treatment.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | February 7, 2025 |
| Main results expected | June 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | December 5, 2025 |
| Trial ID | NCT06758700 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with extensive-stage SCLC who progressed after at least one chemotherapy, have measurable disease, ECOG 0–1, expected survival ≥3 months, and tumors identified as c-Myc–driven/FBXW2/MYC high expression are ideal candidates.
✕Probably not a fit
Patients without measurable lesions, without c-Myc/FBXW2/MYC overexpression, with severe organ dysfunction or poor performance status, or who are pregnant or breastfeeding are unlikely to receive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 interventional study gives teniposide to adults (18–75) with extensive-stage small cell lung cancer who have progressed after at least one prior chemotherapy and whose tumors show c-Myc/FBXW2 high expression. Eligible patients must have measurable disease, ECOG performance status 0–1, and an expected survival of at least three months. Participants will receive scheduled teniposide dosing with regular safety checks and tumor response assessments. The trial will record response rates, progression-free survival, adverse events, and explore whether FBXW2/MYC expression levels correlate with treatment benefit.
Why it matters
Potential benefit: If successful, this approach could provide a biomarker-selected treatment option that improves disease control for patients with c-Myc–driven ES-SCLC after standard therapies fail.
How similar studies have gone: Teniposide and other topoisomerase II inhibitors have historical use in SCLC, but selecting patients by c-Myc/FBXW2 status is a newer strategy with largely preclinical support and limited clinical proof to date.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. extensive stage small cell lung cancer 2. Progression after receiving at least one chemotherapy drug treatment in the past; 3. ECOG score 0-1 4. c-Myc-driven 5. Expected survival period ≥3 months 6. Age: 18-75 years old; 7. The informed consent form complies with the ICH-GCP principles. Exclusion Criteria: 1. No measurable lesions 2. Other severe and persistent diseases or organ system dysfunction; 3. Women planning pregnancy or men planning family planning; 4. Women who are pregnant or breastfeeding; 5. Those who cannot follow the research protocol provided by the investigator.
Where it's running
-
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: jiale Wang
- Email: wangjiale200008@163.com
- Phone: +86 21 65115006
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Early intervention strategies for lung cancer detection
This study is testing if using low-dose CT scans in community health centers can help find lung cancer earlier in people aged 40-75 who don't have a history of the disease.
-
Trop2- and EpCAM-targeted PET/CT to help distinguish non-small cell lung cancer
This project will test whether PET/CT scans that target Trop2 and EpCAM can show protein expression in tumors of people with suspected non-small cell lung cancer.
-
Cemiplimab guided by ctDNA levels (PALACE)
This study will see if starting adults with advanced (stage IIIB/C or IV) non-small cell lung cancer and PD-L1 ≥50% on cemiplimab, then using ctDNA and early scans to decide whether to add chemotherapy, can improve overall survival.
-
AI-assisted longitudinal CT to guide indeterminate lung nodules
This trial tests whether giving doctors an AI report that tracks nodules over serial CT scans helps reduce unnecessary benign lung resections in patients with indeterminate nodules.
-
MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC
This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.
-
Telerehabilitation exercise program after lung cancer surgery
A remote rehabilitation program with guided exercises is tested to help adults after lung cancer surgery recover better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.